Tortugas Neuroscience Raises $106M in Seed and Series A Round to Advance CNS Drug Pipeline

Why It Matters

The capital injection positions Tortugas to address sizable unmet needs in CNS disorders, potentially reshaping treatment paradigms with differentiated, convenient oral therapies. Success could attract further investment into niche neuro‑drug pipelines and pressure incumbents to innovate dosing regimens.

Key Takeaways

• Tortugas raised $106 million to fund four CNS drug programs.
• TRTL‑107 targets schizophrenia as a single‑molecule dopamine/serotonin modulator.
• TRTL‑913 aims to treat tinnitus, an unmet FDA‑approved indication.
• Mid‑stage programs include epilepsy (TRTL‑729) and encephalopathy (TRTL‑118).
• Funding led by Cure Ventures, The Column Group, AN Venture Partners.

Pulse Analysis

The $106 million raise underscores a growing appetite among venture capitalists for focused neuro‑pharma ventures that can de‑risk late‑stage development. By acquiring in‑licensed assets with validated targets, Tortugas sidesteps early discovery uncertainty and accelerates toward pivotal trials. This model mirrors recent trends where specialty investors back platforms that bundle multiple indications under a single commercial strategy, leveraging shared manufacturing and regulatory pathways to maximize return on R&D spend.

Tortugas’s pipeline tackles both high‑volume and niche CNS markets. TRTL‑107 combines dopamine D₂/D₃ partial agonism with 5‑HT₂A antagonism, aiming to simplify schizophrenia therapy into a once‑daily pill—a clear advantage over multi‑dose regimens. Meanwhile, TRTL‑913 targets tinnitus, a condition lacking FDA‑approved treatments, offering a potential first‑in‑class solution. The mid‑stage candidates, TRTL‑729 for focal epilepsy and TRTL‑118 for reversible encephalopathies, address disorders with substantial patient populations and unmet therapeutic gaps, positioning the company for multiple revenue streams once commercialized.

Leadership experience adds credibility; both CEO Jeff Jonas and R&D head Al Robichaud previously drove Sage Therapeutics, which successfully navigated a partnership with Biogen to launch the first oral post‑partum depression drug. Their track record suggests Tortugas can manage complex regulatory pathways and partnership negotiations. If the Phase 2 readouts meet expectations, the company could become an attractive acquisition target for larger pharma players seeking to bolster their CNS portfolios, while also offering early‑stage investors a high‑growth opportunity in a traditionally high‑risk therapeutic area.

Deal Summary

Tortugas Neuroscience announced a $106 million financing round spanning its seed and Series A rounds, led by Cure Ventures with co‑lead investors The Column Group and AN Venture Partners. The capital will fund development of four in‑licensed CNS drugs, including candidates from Hansoh Pharmaceutical Group and Eisai. The round was disclosed on April 21, 2026.